Grant: CIHR Fellowship
Direct Payment
$150,000.00
A novel pharmacological strategy to boost innate immunity and provide broad-spectrum antimicrobial activity through hypoxia-inducible factor-1 (HIF-1)
FY 2011-12
Summary
The widespread and rapid emergence of multi-drug resistant (MDR) bacterial pathogens pose ever-increasing threats to public health. Persistent infections with these superbugs such as MDR Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa are associated with prolonged hospitalizations, as well as increased costs and frequency of poor outcomes or death. Each year, infections from MDR bacteria cause nearly 100,000 deaths in the United States alone. Thus, new and improved strategies to combat infections to prevent the emergence of MDR organisms are needed. This proposal describes a new pharmacological approach to treat microbial infections by boosting the immune system. Recent studies as well as highly promising preliminary data generated from our lab led to the hypothesis that a protein called HIF-1 can significantly enhance host immunity, thus increasing bacterial killing during infections. Using an array of advanced cell biological, genetic and microbiological tools combined with microscopy I will (a) fully characterize how HIF-1 enhances immune cell killing of bacteria (b) extensively explore the role of HIF-1 in bacteria killing using mutant mouse models, and (c) evaluate the efficacy of two HIF-1 drugs recently designed in our lab, at killing MDR bacteria under different infection criteria using a mouse model of MRSA infections. Results from this work will offer new insight into the mechanisms of boosting host immunity and will generate new strategies to eradicate a variety of bacterial infections.
Department
Program
CIHR Fellowship
Recipient
Location
California, United States of America
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
241911
Name
Lin Ann
Region
California
Country
United States of America
Orgtype
Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
A novel pharmacological strategy to boost innate immunity and provide broad-spectrum antimicrobial activity through hypoxia-inducible factor-1 (HIF-1)
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Antimicrobial Therapy; Hypoxia Inducible Factor-1; Immunology; Mice; Multi-Drug Resistance Bacteria; Neutrophil Extracellular Traps; Phagocytic Cells
Abstract
The widespread and rapid emergence of multi-drug resistant (MDR) bacterial pathogens pose ever-increasing threats to public health. Persistent infections with these superbugs such as MDR Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa are associated with prolonged hospitalizations, as well as increased costs and frequency of poor outcomes or death. Each year, infections from MDR bacteria cause nearly 100,000 deaths in the United States alone. Thus, new and improved strategies to combat infections to prevent the emergence of MDR organisms are needed. This proposal describes a new pharmacological approach to treat microbial infections by boosting the immune system. Recent studies as well as highly promising preliminary data generated from our lab led to the hypothesis that a protein called HIF-1 can significantly enhance host immunity, thus increasing bacterial killing during infections. Using an array of advanced cell biological, genetic and microbiological tools combined with microscopy I will (a) fully characterize how HIF-1 enhances immune cell killing of bacteria (b) extensively explore the role of HIF-1 in bacteria killing using mutant mouse models, and (c) evaluate the efficacy of two HIF-1 drugs recently designed in our lab, at killing MDR bacteria under different infection criteria using a mouse model of MRSA infections. Results from this work will offer new insight into the mechanisms of boosting host immunity and will generate new strategies to eradicate a variety of bacterial infections.
Competitiondate
201110
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Lin, Ann
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~